Hdl therapeutics
Cardiovascular device company specializing in the field of reversing coronary atherosclerosis
About Hdl therapeutics
HDL Therapeutics, Inc. is a pioneering company in the medical device industry, focusing on the treatment of coronary atherosclerosis in patients with Homozygous Familial Hypercholesterolemia (HoFH). The company has developed a unique acute care therapeutic device that transforms a patient's own plasma into an agent capable of rapidly reversing atherosclerosis. This patented technology is designed to facilitate the rapid regression of plaque in the coronary arteries, offering a novel solution for a condition that is otherwise difficult to manage. HDL Therapeutics operates in the healthcare market, specifically targeting patients with severe cholesterol disorders. The business model revolves around the development and eventual commercialization of its investigational device, which is currently limited by federal law to investigational use. Revenue generation is expected to come from the sale and licensing of this device once it receives regulatory approval. The company also has a novel SARS-CoV-2 Viral Delipidation Therapy in development, aimed at enhancing immune response and offering a faster, more cost-effective method of treatment.
Source: Dealroom company dataNews
Open roles
Hdl therapeutics in the Vero Beach ecosystem
The Hdl therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Hdl therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Hdl therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.


